title: Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.
abstract: Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83% of these patients. Normal serum copper levels at baseline (median, 130 microg/dl; range, 50-227 microg/dl) fell to the target range of <50 microg/dl (median, 42 microg/dl; range, 12-118 microg/dl) after two months. Penicillamine-induced hypocupremia was well tolerated for months. Drug-related myelosuppression, elevated liver function tests, and skin rash rapidly reversed with copper repletion. Median survival was 11.3 months, and progression-free survival was 7.1 months. Achievement of hypocupremia did not significantly increase survival. Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme.
authors.affiliation: Department of Interdisciplinary Oncology and Neurosurgery, University of South Florida College of Medicine and Neuro-Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL 33620, USA. brem@moffitt.usf.edu
authors.forename: Steven
authors.initials: S
authors.lastname: Brem
authors.forename: Stuart A
authors.initials: SA
authors.lastname: Grossman
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Carson
authors.forename: Pamela
authors.initials: P
authors.lastname: New
authors.forename: Surasak
authors.initials: S
authors.lastname: Phuphanich
authors.forename: Jane B
authors.initials: JB
authors.lastname: Alavi
authors.forename: Tom
authors.initials: T
authors.lastname: Mikkelsen
authors.forename: Joy D
authors.initials: JD
authors.lastname: Fisher
mesh_terms: D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D002614:Chelating Agents / Q000633:toxicity*; D003300:Copper / Q000097:blood*; D004035:Diet Therapy; D005260:Female; D005909:Glioblastoma / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010396:Penicillamine / Q000633:toxicity*; D016019:Survival Analysis
chemical_list: D002614:Chelating Agents; D003300:Copper; D010396:Penicillamine